Do you need cataract surgery? If so, you may be eligible to participate in a research study conducted by RxSight® to further evaluate an FDA-approved intraocular lens (IOL), the RxSight Light Adjustable Lens (LAL®). The LAL allows your doctor to adjust the power of the lens after it has been implanted in your eye to improve distance vision.
Approximately 500 men and women will participate in this study. During this study, patients will have a 66% (2/3) chance of receiving a Light Adjustable Lens™, and a 33% (1/3) chance of receiving a commercially available monofocal IOL. Patients will need to return to the doctor’s office for evaluation over a 6-month period.
A formal consent process and eye exam are required before decisions can be made about your enrollment and willingness to be involved with this study.
Please fill out this form and our local study team will contact you shortly.
To learn more about this study and whether you may be eligible to participate, you or your eye doctor may contact the nearest study research staff directly.
Vold Vision
2783 N Shiloh Dr
Fayetteville, AR 72704
Contact: Clinical Research Department
(479) 435-6440
Reeve Woods Eye Center
280 Cohasset Rd
Chico, CA 95926
Contact: Emma Chauvin
emma@reevewoods.com
(530) 899-2244 x131
The Eye Institute of West Florida
1225 West Bay Dr
Largo, FL 33770
Contact: Renee C. Bondurant, BS, CCRC
renee.bondurant@eyespecialist.com
(727) 581-8706
Newsom Eye
4211 US Hwy 27 N
Sebring, FL 33870
Contact: Xiomara Marcano
x.marcano@newsomeeye.net
(863) 385-1544 x109
Vance Thompson Vision
2600 Jefferson St, Suite 200
Alexandria, MN 56378
Contact: Abby Garofalo
abby.garofalo@vancethompsonvision.com
Miranda Danielson
miranda.danielson@vancethompsonvision.com
(320) 391-9050
Vance Thompson Vision
4909 S 118th St
Omaha, NE 68137
Contact: Sara Hartnett, CCRC
sarah.hartnett@vancethompsonvision.com
(402) 506-9970
Center for Sight
330 S Rampart Blvd, Suite 360
Las Vegas, NV 89145
Contact: Clinical Research Manager
research@c4slv.com
(702) 724-2005
Cleveland Eye Clinic
7001 S Edgerton Rd, Suite B
Brecksville, OH 44141
Contact: Erin Kus-Kreidler
ekus-kreidler@midwestvision.com
(216) 503-6535
Carolina Eyecare Physicians
1101 Clarity Rd, Suite 100
Mt. Pleasant, SC 29464
Contact: Helga Sandoval, MD
cepresearch@cepmd.com
(843) 380-2499
Vance Thompson Vision
3101 W 57th St
Sioux Falls, SD 57108
Contact: Elle Malmanger
elle.malmanger@vancethompsonvision.com
(605) 371-7083
Focal Point Vision
343 W Sunset, Suite 1
San Antonio, TX 78209
Contact: Lisa Navarro
navarro@focalpointvision.com
(210) 614-3600 x118
Key-Whitman Eye Center
11442 N Central Expressway
Dallas, TX 75235
Contact: Alex Bittermann
alex.bittermann@keywhitman.com
(214) 754-0000 x2295
Slade & Baker Vision
3900 Essex Lane, Suite 101
Houston, TX 77027
Contact: Johnelle Zarutskie
johnelle@visiontexas.com
(713) 626-5544
Texas Eye Research Center
1852 Norwood Plaza Ct, Suite 101
Hurst, TX 76054
Contact: Barrett Bott
bbott@lasikdr.com
(817) 540-6060 x2060
Approved use: The Light Adjustable Lens and Light Delivery Device (LDD) system is approved for patients who have a cataract and need surgery for it, have corneal astigmatism (at least 0.75 diopters) before surgery, and do not have preexisting macular disease.
Who should not receive this treatment? The Light Adjustable Lens and LDD system should not be used if you are taking medications that may increase your sensitivity to ultraviolet (UV) light; if you are taking a medication that is considered harmful to your retina; if you have a history of herpes eye infection or uncontrollable eye movements (nystagmus); or if you are unable to comply with your doctor’s schedule of LDD light treatments and instructions for wearing special UV-protective glasses for several weeks following cataract surgery.
What warnings should I be aware of? Preexisting macular disease and certain eye conditions may increase the risk of complications. Your doctor will determine if you are a good candidate for the Light Adjustable Lens. If you have any complications during your cataract surgery before the Light Adjustable Lens is implanted, you may need to have another intraocular lens (IOL) implanted instead of the Light Adjustable Lens.
What precautions should I be aware of? The safety and effectiveness of the Light Adjustable Lens and LDD have not been established in patients with certain preexisting eye conditions or in patients who experience certain complications during cataract surgery. You should discuss these issues with your doctor. Following surgery, you must wear the special UV-protective glasses during all waking hours for about 4 to 5 weeks and comply with your doctor’s schedule of LDD light treatments. Failure to wear the UV-protective glasses can result in an unpredicted vision change or loss of vision quality after exposure to UV light, such as from sunlight. This may require a second surgery to remove the Light Adjustable Lens from your eye and replace it with another IOL.
What are the potential risks? As with any surgical procedure, there are risks associated with cataract surgery and IOL implantation. Please discuss these risks with your doctor. Potential risks associated with LDD light treatments include mild alterations to color perceptions; temporary scratchiness, irritation, or dryness to the front part of your eye; and activation of a previously undiagnosed herpes eye infection. Longer lasting and serious adverse events related to the UV light exposure are possible, but rare. There is a small chance that your vision could be made worse or that you may require additional surgery as a result of a complication.
Caution: Federal law restricts this device to sale by or on the order of a physician.
©2023 RxSIGHT. All Rights Reserved. COM-1043 Rev. B
The LAL provides optimized vision for patient satisfaction.2
LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).
Since the LAL is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.
The LAL offers LASIK-like accuracy in cataract surgery.2,3
92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).
Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.
The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.
The LAL corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.